Rivaroxaban for PE

In this large trial of 4832 patients with PE, they were randomized to rivaroxaban (15mg bid for 3 weeks, then 20mg qday) or enoxaparin-warfarin. Recurrent VTE occurred at about the same rate in both groups (2.1% of rivaroxaban group and 1.8% of enoxaparin-warfarin group), but major bleeding was less common with rivaroxaban (1.1% vs 2.2%). Pending FDA approval, rivaroxaban may become the new standard for VTE treatment (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment